Phase 2 N=120 Provoked Craving Relief Study by NRT
Smoking Cessation
Primary: Mean Change From Baseline in Nicotine Craving Score on a VAS — -11.3; -1.7; -4.6; -28.2 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation
Neurotic Excoriation · Pathologic Skin Picking · Psychogenic Excoriation
Primary: The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) Will be the Primary Outcome Measure — 15.25; 16.13 units on a scale
Phase 2 N=22 Metabolic Effects of Paricalcitol
Chronic Kidney Disease
Primary: Glucose Area Under the Curve (AUC) — 20817; 21139 mg*min/dL
Phase 2 N=14 Marinol in Trichotillomania or Obsessive Compulsive Disorder
Trichotillomania · Obsessive Compulsive Disorder
Primary: Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score — 8.71 units on a scale
Phase 2 N=55 Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis
Primary: Histological Improvement of at Least 2 Points in NAFLD Activity Score (NAS) on Liver Biopsy After One Year. — -1.6; -0.1 NAS score units
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 2 N=160 Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
Cancer
Primary: Overall Survival — 8.4; 6.7 months — p=0.352
Phase 2 N=48 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
Essential Thrombocythemia · Polycythemia Vera · Primary Myelofibrosis
Primary: Overall Response Rate — 0.26 Proportion of participants
Phase 2 N=70 A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients
Kidney Transplantation
Primary: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) for Tacrolimus — 215.1; 206.6; 200.7; 197.6 ng*hr/mL
Phase 2 N=41 Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Myelofibrosis
Primary: Percentage of Participants With at Least 1 Adverse Event From Baseline Through Week 16 — 78.0 Percentage of participants
Phase 2 N=183 An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
Pneumonia · Bacterial Pneumonia · Ventilator-Associated Pneumonia
Primary: Clinical Response Rates and 95% Confidence Intervals at the Test-of-Cure Assessment. — 63.9; 66.0; 64.4; 50.0 Percentage of participants
Phase 2 N=40 Effect of Milnacipran in Chronic Neuropathic Low Back Pain
Low Back Pain
Primary: Effect Size of VAS Pain — 24.8; 31.3 units on a scale
Phase 2 N=133 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..
Nerve Pain
Primary: Change From Baseline to Days 24-28 in Numerical Rating Scale (NRS) Average Pain Score. — -1.53; -1.54; -1.44 Scores on a scale
Phase 2 N=96 Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
Renal Impairment
Primary: Change From Baseline to Month 12 in Serum Creatinine — 2.52; 2.10; 2.22; 0.19 mg/dL — p=0.459
Phase 2 N=134 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
Neuropathic Pain
Primary: Change From Baseline to Days 24-28 in Numerical Rating Scale (NRS) Average Pain Score. — -1.35; -1.50; -1.61 Scores on a scale